Now showing items 31-40 of 54
Prediction of thioguanine-induced cytotoxicity by dual-parameter flow cytometric analysis
(Springer-Verlag, 1989-10)
A method is presented for the quantitative analysis of delayed cytokinetic effects resulting from the treatment of L1210 cells with 6-thioguanine (TG). By using dual-parameter (DNA/protein) flow cytometry, we could observe ...
Comparison of the adrenalytic activity of mitotane and a methylated homolog on normal adrenal cortex and adrenal cortical carcinoma
(Springer-Verlag, 1993-11)
Mitotane is an important adrenalytic drug for the treatment of adrenal cancer whose use is limited by toxicity. Reports from another laboratory indicated that a methylated homolog of Mitotane (Mitometh) tested in guinea ...
A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer
(Kluwer Academic Publishers; Springer Science + Business Media, Inc., 2005-12)
Background . Pancreatic cancer is amongst the most chemoresistant malignancies. Expression of the cyclooxygenase-2 (COX-2) enzyme plays a major role in tumor progression and resistance to therapy. A Phase II study was ...
Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: A Southwest Oncology Group study
(Kluwer Academic Publishers; Springer Science+Business Media, 1990-02)
Patient with advanced adenocarcinoma of the pancreas and no prior chemotherapy were treated on a Phase II trial of mitoxantrone. Doses were adjusted for hepatic dysfunction as defined by bilirubin. Twenty-four patients ...
Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer
(Kluwer Academic Publishers; Springer Science+Business Media, 1993-02)
Eighty-six patients with advanced colorectal, gastric or pancreatic carcinoma and no prior exposure to chemotherapy were treated with brequinar sodium. Brequinar was administered at a median weekly dose of 1200 mg/m 2 ...
Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs
(Kluwer Academic Publishers; Springer Science+Business Media, 2004-11)
Objectives : CCI-779 is an ester of the immunosuppressive agent sirolimus (rapamycin) that causes cell-cycle arrest at G1 via inhibition of key signaling pathways resulting in inhibition of RNA translation. Antitumor ...
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
(Kluwer Academic Publishers; Springer Science + Business Media, Inc., 2005-08)
Purpose : Loss of PTEN, which is common in glioblastoma multiforme (GBM), results in activation of the mammalian target of rapapmycin (mTOR), thereby increasing mRNA translation of a number of key proteins required for ...
Multicenter phase II study of brequinar sodium in patients with advanced lung cancer
(Springer-Verlag, 1993-01)
A total of 53 patients with advanced lung cancer [non-small-cell (NSC), 21; small-cell (SC), 32] were treated with brequinar sodium. All of the NSC patients were chemotherapy-naive, but 31/32 (97%) SC patients had failed ...
Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck
(Springer-Verlag, 1992-03)
A total of 19 patients with advanced squamous-cell carcinoma of the head and neck who had not previously been exposed to chemotherapy were treated with brequinar sodium as first-line chemotherapy. Brequinar was given ...
A Phase I Clinical Trial of Spicamycin Derivative KRN5500 (NSC 650426) Using a Phase I Accelerated Titration “2B” Design
(Kluwer Academic Publishers; Springer Science+Business Media, 2003-02)
The spicamycin derivative KRN5500 was considered as a potential anti-cancer agent based on in vitro and preclinical studies. A Phase I study involving 24 cancer patients in whom tumors were refractory to all other conventional ...